Founded in 1991, Albany Molecular Research, Inc. (Nasdaq: AMRI) is a
chemistry-based drug discovery, development and manufacturing company, focusing
on small molecule prescription drugs. AMRI provides chemistry expertise at all
stages of the drug discovery process (see chart below), from identifying leads
for validated targets, to lead optimization, scale-up, in vitro metabolism, and
cGMP synthesis and manufacturing for clinical trials and commercial products. To
complement these capabilities, AMRI maintains an in-house analytical chemistry
department with state-of-the-art analytical equipment.
Company research has led to dozens of issued and pending patents, including
important patents for the active ingredient in the non-sedating antihistamine,
Allegra, developed and marketed by Sanofi-Aventis. A key strategy of the company
is to develop, acquire and apply promising new technology in order to bring
added value to drug discovery and development projects.
AMRI maintains both a comprehensive chemistry services platform and a
proprietary R&D platform. Since its inception, AMRI has provided contract
chemistry services to many of the world's leading pharmaceutical and
biotechnology companies. AMRI's chemistry services platform includes medicinal
chemistry, chemical process research and development, analytical chemistry and
cGMP manufacturing. In addition, the company maintains several unique and/or
proprietary technologies, including one of the industry's largest collections of
natural products-based extracts (for lead discovery), biocatalysis, in vitro
biology and fermentation. Customers collaborate with AMRI for a number of
reasons: to complement their existing resources, to use AMRI as a chemistry
department when none exists, to access unique technologies and expertise, and
many others. For information about AMRI's chemistry services, use the following
links: discovery services, preclinical services, clinical services and
In addition to providing chemistry services, AMRI also conducts its own
proprietary research and development, with the goal of licensing preclinical and
clinical compounds to a commercialization partner. The company has internal
research programs in a number of therapeutic areas, including CNS/neurology,
oncology, immune disorders, irritable bowel disease and anti-inflammation. These
programs make use of AMRI's compound collections and expertise in high
throughput screening, medicinal chemistry, natural products chemistry and
biocatalysis. AMRI's proprietary R&D platform also includes collaborations in
which customers may access one or more of the company's unique technologies,
including natural products, high throughput screening, biocatalysis and
fermentation. Internal research programs are at various stages of development,
with several projects available for outlicensing. For more information about
AMRI's proprietary research, please visit our R&D pages.
Ping Wang, Ph.D.
We speak with researchers behind the latest advancement in graphene hBN research that could boost the development of next-generation electronic and quantum devices.
Dr. Laurene Tetard
AZoNano speaks with Dr. Laurene Tetard from the University of Central Florida about her upcoming research into the development of nanotechnology that can detect animal-borne diseases. The hope is that such technology can be used to help rapidly control infected mosquito populations to protect public
Dr. Amir Sheikhi
AZoNano speaks with Dr. Amir Sheikhi from Pennsylvania State University about his research into creating a new group of nanomaterials designed to capture chemotherapy drugs before they impact healthy tissue, amending a fault traditionally associated with conventional nanoparticles.
The Filmetrics F40 turns your benchtop microscope into an instrument for measuring thickness and refractive index.
Nikalyte’s NL-UHV is a state-of-the-art tool that allows the generation and deposition of nanoparticles in an Ultra-High vacuum onto a sample to create a functionalized surface.
The Filmetrics® F54-XY-200 is a thickness measurement tool created for automated sequence measurement. It is available in various wavelength configuration options, allowing compatibility with a range of film thickness measurement applications.